Overview of the Offering#
Avalo Therapeutics, Inc. has announced a public offering of approximately 19.7 million shares of common stock, along with pre-funded warrants for an additional 1.4 million shares. The common stock is priced at $17.75 per share, while the pre-funded warrants are priced slightly lower at $17.749 each. This pricing is above the current market price of $16.26, although Avalo's stock has seen a remarkable increase of 240% over the past year.
Financial Details#
The total gross proceeds from this offering are expected to be around $375 million before accounting for any underwriting fees or expenses. The offering is set to close on May 7, 2026, pending standard closing conditions. Avalo has also given underwriters a 30-day option to purchase up to 3.2 million additional shares under the same terms.
Purpose of the Funds#
Avalo plans to use the funds raised from this offering, along with its existing cash and short-term investments, to further develop its lead drug candidate, abdakibart. This drug is currently in Phase 3 clinical trials, and the company aims to release topline data soon. Additionally, the funds will support general corporate needs and working capital.
Company Background#
Avalo Therapeutics is a biotechnology firm focused on developing treatments for immune-mediated inflammatory diseases. Its lead product, abdakibart, is an anti-IL-1β monoclonal antibody that has recently shown promising results in a Phase 2 trial for hidradenitis suppurativa, a chronic skin condition. Analysts have expressed confidence in Avalo's future, with several firms maintaining positive ratings and price targets for the company as it continues its clinical development efforts.